Differentiation of Human Induced Pluripotent Stem Cells into Keratinocytes.
epidermal biology
iPSC
iPSC-derived keratinocytes
induced pluripotent stem cell
keratinocytes
skin diseases
Journal
Current protocols
ISSN: 2691-1299
Titre abrégé: Curr Protoc
Pays: United States
ID NLM: 101773894
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
entrez:
6
4
2022
pubmed:
7
4
2022
medline:
8
4
2022
Statut:
ppublish
Résumé
Investigating basic biological mechanisms underlying human diseases relies on the availability of sufficient quantities of patient cells. As most primary somatic cells have a limited lifespan, obtaining sufficient material for biological studies has been a challenge. The development of induced pluripotent stem cell (iPSC) technology has been a game changer, especially in the field of rare genetic disorders. iPSC are essentially immortal, can be stored indefinitely, and can thus be used to generate defined somatic cells in unlimited quantities. Further, the availability of genome editing technologies, such as CRISPR/CAS, has provided us with the opportunity to create "designer" iPSC lines with defined genetic characteristics. A major advancement in biological research stems from the development of methods to direct iPSC differentiation into defined cell types. In this article, we provide the basic protocol for the generation of human iPSC-derived keratinocytes (iPSC-K). These cells have the characteristics of basal epidermal keratinocytes and represent a tool for the investigation of normal epidermal biology, as well as genetic and acquired skin disorders. © 2022 The Authors. Current Protocols published by Wiley Periodicals LLC. Basic Protocol: Directed differentiation of human iPSC into keratinocytes Support Protocol 1: Coating cell culture dishes or plates with Vitronectin XF
Identifiants
pubmed: 35384405
doi: 10.1002/cpz1.408
pmc: PMC9011197
mid: NIHMS1788770
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e408Subventions
Organisme : National Foundation for Ectodermal Dysplasias
Organisme : NIH HHS
ID : R21EY029081
Pays : United States
Organisme : NEI NIH HHS
ID : R21 EY029081
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR072621
Pays : United States
Organisme : NIH HHS
ID : R01AR072621
Pays : United States
Informations de copyright
© 2022 The Authors. Current Protocols published by Wiley Periodicals LLC.
Références
PLoS One. 2013 Oct 11;8(10):e77673
pubmed: 24147053
Prog Clin Biol Res. 1977;17:493-500
pubmed: 928463
Expert Rev Endocrinol Metab. 2012 Jul;7(4):461-472
pubmed: 23144648
Science. 2009 May 8;324(5928):797-801
pubmed: 19325077
Stem Cell Rev Rep. 2016 Feb;12(1):54-72
pubmed: 26424535
Nat Protoc. 2008;3(7):1180-6
pubmed: 18600223
Stem Cell Reports. 2014 Apr 24;2(5):675-89
pubmed: 24936454
Proc Natl Acad Sci U S A. 2019 Dec 9;:
pubmed: 31818947
Expert Opin Biol Ther. 2010 Jul;10(7):1089-103
pubmed: 20528610
Prog Mol Biol Transl Sci. 2013;116:95-118
pubmed: 23481192
J Clin Invest. 2010 Jul;120(7):2619-26
pubmed: 20516646
Curr Protoc. 2022 Apr;2(4):e408
pubmed: 35384405
Proc Natl Acad Sci U S A. 2011 May 24;108(21):8797-802
pubmed: 21555586
Curr Protoc Stem Cell Biol. 2020 Sep;54(1):e117
pubmed: 32649060
Sci Transl Med. 2014 Nov 26;6(264):264ra163
pubmed: 25429056
Front Genet. 2021 Aug 06;12:714764
pubmed: 34422015
Cells. 2021 Jun 11;10(6):
pubmed: 34208270
Am J Med Genet A. 2014 Oct;164A(10):2443-54
pubmed: 24665072
Cell. 2007 Nov 30;131(5):861-72
pubmed: 18035408
J Invest Dermatol. 2018 Jul;138(7):1662-1665
pubmed: 29481901
Nat Commun. 2020 May 19;11(1):2493
pubmed: 32427826